PF 03709270 is an orally available ester prodrug form of sulopenem, with broad-spectrum antibacterial activity against most gram-positive and gram-negative bacteria.

Petroselinic acid, a positional isomer of oleic acid, is isolated from the vegetable oil of Coriandrum sativum fruits.

Perlapine (AW-14233.

Perisesaccharide C is an oligosaccharide isolated from the root barks of Periploca sepium.

Perisesaccharide B is an oligosaccharide isolated from the root barks of Periploca sepium.

Perhexiline is a prophylactic antianginal agent that inhibits carnitine palmitoyltransferase (CPT1/CPT2).

Peptide Fz7-21 is a potent, selective peptide inhibitor of Frizzled 7 receptor, inhibits exogenous WNT3A stimulated Wnt-β-catenin signaling in HEK293 cells with IC50 of 100 nM.

Pentanoic acid, a short-chain fatty acid, is a product of bacterial metabolism and are associated with allergic skin disorders. Pentanoic acid activates ROCK signaling pathway.

PDK1 inhibitor is a potent and selective inhibitor of PDK1 with potential as anticancer agent..

PDEδ-IN-99 is a novel potent K-Ras-PDEδ inhibitor that binds to the farnesyl binding pocket of PDEδ with Kd of 8±4 nM..

PDE4D-IN-26b is a potent, highly selective PDE4D inhibitor with IC50 of 0.6 nM, displays 75-fold lower activity against the PDE4A, B, and C subtypes, also exhibits 18,000-fold decreased potency against other PDE family members.

PDE2 inhibitor 4 is a potent, selective, orally available inhibitor of PDE2 with IC50 of 2 nM, displays high selectivity versus other PDE isoforms.

PDE1-IN-2 is an inhibitor of PDE1 extracted from patent WO2016/55618 A1, example 31; has IC50 values of 6, 140 and 164 nM for PDE1C, PDE1B and PDE1A, respectvely.

PDE10A-IN-32 is a potent, highly selective, brain penetrant PDE10A inhibitor with IC50 of 0.14 nM, displays no significant activity against other PDEs (IC50>1,000 nM)..

PDE10A-IN-31 is a potent, highly selective PDE10A inhibitor with IC50 of 2 nM for both rPDE10A and hPDE10A.

PD1-PD L1 inhibitor Polaris is a novel potent, small molecule inhibitor of PD-1/PD-L1 interaction (IC50=0.1-10 nM in ELISA assays) with anti-cancer activity.

PD1-IN-2 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.

PCSK9-IN-7l is a potent, small molecule PCSK9 mRNA translation inhibitor with IC50 of 1.37 uM, shows limited bone marrow toxicity (IC50=27.1 uM)..

PCSK9 modulator 10 is a highly potent, orally active PCSK9 modulator that inhibits PCSK9 production in HepG2 cells with IC50 of 0.036 nM.

PCI-33380 is an irreversible Bruton's Tyrosine Kinase (BTK) inhibitor (fluorescent probe).

PCC0104005 (PCC-0104005) is a novel modulator of serotonin, dopamine, and noradrenaline receptors, including partial agonism at dopamine D2, D3, D4, serotonin 5-HT1A, and 5-HT2A receptors and antagonism at 5-HT2B, 5-HT6, and 5-HT7 receptors.

PCARBTP is a derivative, potent, specific Kv1.3 channel inhibitor, reduces cell viability and efficiently kills B16F10 cancer cells at 1 uM.

PCAF BRD inhibitor L-45 is a potent, selective, and cell-active PCAF bromodomain inhibitor with Ki of 47 nM in HTRF assays, >4,500-fold selectivity over BRD4.

PC945 is a novel broad spectrum antifungal agent that potently inhibits Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B) with IC50 of 0.23 and 0.22 uM, respectively.

PC1244 is a long acting fungicidal azole that targets A. fumigatus CYP51A and CYP51B, inhibits ergosterol synthesis in A. fumigatus with IC50 of 8 nM.

PBI-4050 (Setogepram, PBI4050) is a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively.

PBI-4050 (Setogepram, PBI4050) is a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively.

PBF509 (PBF-509, NIR 178) is a novel selective and potent Adenosine A2A Receptor (A2AR) antagonist, antagonizes A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 and 8.2 nM, respectively.

Paullinic acid is a long-chain fatty acid that has been detected in multiple biofluids, such as blood and urine.

PAT-505 (PAT 505, PAT505) is a potent, selective, noncompetitive, and orally active autotaxin inhibitor with IC50 of 2.0 nM against the lysoPLD activity of human ATX.